X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (30231) 30231
Book Chapter (136) 136
Magazine Article (103) 103
Newspaper Article (82) 82
Newsletter (66) 66
Book / eBook (33) 33
Web Resource (25) 25
Conference Proceeding (16) 16
Publication (16) 16
Dissertation (5) 5
Book Review (2) 2
Reference (2) 2
Trade Publication Article (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (26319) 26319
platelet aggregation inhibitors - therapeutic use (18702) 18702
male (12964) 12964
female (11626) 11626
middle aged (9185) 9185
aged (8355) 8355
aspirin - therapeutic use (6641) 6641
cardiac & cardiovascular systems (5844) 5844
treatment outcome (5757) 5757
aspirin (5405) 5405
risk factors (5198) 5198
ticlopidine - analogs & derivatives (5145) 5145
animals (4577) 4577
ticlopidine - therapeutic use (4572) 4572
clopidogrel (4414) 4414
adult (4220) 4220
anticoagulants - therapeutic use (4086) 4086
peripheral vascular disease (3943) 3943
platelet aggregation inhibitors - adverse effects (3913) 3913
hematology (3601) 3601
platelet aggregation - drug effects (3431) 3431
thrombosis (3285) 3285
platelet aggregation inhibitors - administration & dosage (3252) 3252
drug therapy, combination (3223) 3223
pharmacology & pharmacy (3198) 3198
platelet aggregation inhibitors - pharmacology (2945) 2945
blood platelets (2838) 2838
time factors (2831) 2831
platelets (2689) 2689
stents (2592) 2592
percutaneous coronary intervention (2566) 2566
stroke (2515) 2515
medicine, general & internal (2473) 2473
aged, 80 and over (2464) 2464
risk (2415) 2415
blood platelets - drug effects (2308) 2308
fibrinolytic agents - therapeutic use (2285) 2285
prevention (2135) 2135
mortality (2123) 2123
care and treatment (2103) 2103
abridged index medicus (2094) 2094
prospective studies (2066) 2066
therapy (2033) 2033
acute coronary syndromes (1982) 1982
myocardial-infarction (1970) 1970
retrospective studies (1957) 1957
surgery (1944) 1944
drug therapy (1939) 1939
antiplatelet therapy (1870) 1870
aggregation (1817) 1817
anticoagulants (1802) 1802
cardiology (1794) 1794
platelet glycoprotein gpiib-iiia complex - antagonists & inhibitors (1761) 1761
follow-up studies (1725) 1725
myocardial infarction - drug therapy (1712) 1712
platelet aggregation (1710) 1710
heart attacks (1700) 1700
analysis (1695) 1695
risk assessment (1659) 1659
stroke - prevention & control (1631) 1631
angioplasty, balloon, coronary (1618) 1618
blood platelets - metabolism (1609) 1609
medicine & public health (1606) 1606
cardiovascular disease (1571) 1571
randomized controlled trials as topic (1560) 1560
aspirin - administration & dosage (1525) 1525
hemorrhage - chemically induced (1520) 1520
cardiovascular (1510) 1510
research (1486) 1486
health aspects (1476) 1476
coronary heart disease (1442) 1442
acute myocardial-infarction (1407) 1407
thrombosis - prevention & control (1406) 1406
clinical neurology (1369) 1369
aspirin - adverse effects (1357) 1357
disease (1333) 1333
dose-response relationship, drug (1320) 1320
cardiovascular diseases (1308) 1308
inhibition (1301) 1301
acute coronary syndrome - drug therapy (1299) 1299
myocardial infarction - therapy (1287) 1287
cardiac patients (1260) 1260
angioplasty (1258) 1258
ticlopidine - adverse effects (1253) 1253
secondary prevention (1246) 1246
management (1228) 1228
activation (1206) 1206
recurrence (1200) 1200
anticoagulants - adverse effects (1187) 1187
clinical trials as topic (1183) 1183
patients (1138) 1138
coronary angiography (1137) 1137
myocardial infarction (1132) 1132
trial (1129) 1129
prognosis (1110) 1110
ticlopidine - administration & dosage (1091) 1091
mice (1084) 1084
inflammation (1083) 1083
heparin - therapeutic use (1080) 1080
platelet activation (1080) 1080
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (28096) 28096
German (635) 635
French (562) 562
Spanish (361) 361
Japanese (353) 353
Russian (277) 277
Italian (222) 222
Chinese (157) 157
Polish (88) 88
Portuguese (55) 55
Dutch (54) 54
Hungarian (30) 30
Czech (29) 29
Turkish (26) 26
Danish (22) 22
Swedish (19) 19
Hebrew (15) 15
Ukrainian (12) 12
Norwegian (11) 11
Finnish (10) 10
Korean (10) 10
Lithuanian (9) 9
Serbian (9) 9
Romanian (6) 6
Croatian (5) 5
Icelandic (4) 4
Slovak (3) 3
Bosnian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The Lancet (British edition), ISSN 0140-6736, 2011, Volume 378, Issue 9798, pp. 1231 - 1243
Summary Background Although most cardiovascular disease occurs in low-income and middle-income countries, little is known about the use of effective secondary prevention medications in these communities... 
Internal Medicine | STROKE | MEDICINE, GENERAL & INTERNAL | RISK-FACTORS | THERAPY | MYOCARDIAL-INFARCTION | AVAILABILITY | HEART-FAILURE | SELF-REPORT | ACUTE CORONARY SYNDROMES | MEDICINES | VALIDITY | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Male | Data Collection | Secondary Prevention | Stroke - drug therapy | Urban Population | Antihypertensive Agents - therapeutic use | Drug Utilization | Cardiovascular Agents - therapeutic use | Developed Countries | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Rural Population | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Coronary Disease - drug therapy | Adult | Female | Aged | Developing Countries | Platelet Aggregation Inhibitors - therapeutic use | Adrenergic beta-Antagonists - therapeutic use | Care and treatment | Research | Cardiovascular diseases | Health aspects | Cardiovascular agents | Studies | Low income groups | Stroke | Households | Socioeconomic factors | Data collection | Cardiovascular disease | Epidemiology | Economic development | Community | Drug use | Antihypertensive Agents/therapeutic use | Angiotensin-Converting Enzyme Inhibitors/therapeutic use | Cardiovascular Agents/therapeutic use | Coronary Disease/drug therapy | Cardiovascular Diseases/prevention & control | Platelet Aggregation Inhibitors/therapeutic use | Stroke/drug therapy | MEDICIN OCH HÄLSOVETENSKAP | Adrenergic beta-Antagonists/therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use | MEDICAL AND HEALTH SCIENCES
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 09/2008, Volume 359, Issue 12, pp. 1238 - 1251
In this large clinical trial, aspirin plus extended-release dipyridamole was found to have an efficacy similar to that of clopidogrel in the prevention of... 
ACTIVE CONTROLLED-TRIALS | HIGH-RISK PATIENTS | TICLOPIDINE | TRANSIENT ISCHEMIC ATTACK | DOUBLE-BLIND | PREVENTION | RANDOMIZED CONTROLLED-TRIAL | ARTERIAL ORIGIN ESPRIT | CEREBRAL-ISCHEMIA | UMCG Approved | NON-INFERIORITY TRIALS | ISSUES | MEDICINE, GENERAL & INTERNAL | PLACEBO | DESIGN | WARFARIN | REGIMENS | Myocardial Infarction - epidemiology | Benzoates - therapeutic use | Ticlopidine - therapeutic use | Humans | Middle Aged | Male | Risk | Secondary Prevention | Aspirin - administration & dosage | Vascular Diseases - mortality | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Aspirin - adverse effects | Platelet Aggregation Inhibitors - administration & dosage | Ticlopidine - adverse effects | Dipyridamole - adverse effects | Female | Stroke - epidemiology | Drug Therapy, Combination | Platelet Aggregation Inhibitors - therapeutic use | Dipyridamole - therapeutic use | Benzimidazoles - therapeutic use | Platelet Aggregation Inhibitors - adverse effects | Brain Ischemia - epidemiology | Stroke - prevention & control | Double-Blind Method | Kaplan-Meier Estimate | Proportional Hazards Models | Brain Ischemia - prevention & control | Factor Analysis, Statistical | Stroke - drug therapy | Ticlopidine - analogs & derivatives | Aged | Hemorrhage - chemically induced | Delayed-Action Preparations | Stroke (Disease) | Aspirin | Usage | Care and treatment | Dipyridamole | Clopidogrel | Health aspects | Stroke | Index Medicus | Abridged Index Medicus | Recurrence | Brain Ischemia | Benzimidazoles | Follow-Up Studies | Neurons and Cognition | Cognition | Hemorrhage | Drug Delivery Systems | Life Sciences | Angiotensin II Type 1 Receptor Blockers | Angiotensin-Converting Enzyme Inhibitors | Vascular Diseases | Mental Status Schedule | Retrospective Studies | Severity of Illness Index | Disability Evaluation | Benzoates | Drug Administration Schedule | International Cooperation | Ticlopidine | Myocardial Infarction | Platelet Aggregation Inhibitors | Santé publique et épidémiologie | Original | Dipyridamole/adverse effects/therapeutic use | Angiotensin-Converting Enzyme Inhibitors/therapeutic use | Recurrence/prevention & control | Benzoates/therapeutic use | Brain Ischemia/epidemiology/prevention & control | MEDICIN OCH HÄLSOVETENSKAP | Platelet Aggregation Inhibitors/administration & dosage/adverse | Combination | MEDICAL AND HEALTH SCIENCES | Aspirin/administration & dosage/adverse effects | Myocardial Infarction/epidemiology | Factor Analysis | Benzimidazoles/therapeutic use | Drug Therapy | Ticlopidine/adverse effects/analogs & derivatives/therapeutic use | effects/therapeutic use | Vascular Diseases/mortality | Hemorrhage/chemically induced | Stroke/drug therapy/epidemiology/prevention & control | Statistical | Kaplan-Meiers Estimate
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 01/2008, Volume 51, Issue 3, pp. 256 - 260
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2016, Volume 387, Issue 10013, pp. 61 - 69
...% of communities and used by 50% of eligible individuals by 2025. We have previously reported that use of these medicines is very low, but now aim to assess how such low use relates to their lack of availability or poor affordability... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | Drug Costs | Platelet Aggregation Inhibitors - economics | Cardiovascular Diseases - drug therapy | Humans | Income | Malaysia | Secondary Prevention | Aspirin - supply & distribution | Urban Population | Angiotensin-Converting Enzyme Inhibitors - supply & distribution | Angiotensin-Converting Enzyme Inhibitors - economics | Sweden | Pakistan | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Iran | Rural Population | China | Adrenergic beta-Antagonists - economics | Brazil | Poland | Aspirin - therapeutic use | Aspirin - economics | Chile | Platelet Aggregation Inhibitors - therapeutic use | Adrenergic beta-Antagonists - therapeutic use | Cardiovascular Agents - economics | Colombia | Argentina | Platelet Aggregation Inhibitors - supply & distribution | Hydroxymethylglutaryl-CoA Reductase Inhibitors - supply & distribution | Hydroxymethylglutaryl-CoA Reductase Inhibitors - economics | United Arab Emirates | Adrenergic beta-Antagonists - supply & distribution | India | Pharmacies | Canada | Cardiovascular Agents - supply & distribution | Cardiovascular Agents - therapeutic use | Bangladesh | Family Characteristics | Developed Countries | Turkey | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | South Africa | Zimbabwe | Developing Countries | Drugs | Prevention | Usage | Cardiovascular diseases | Analysis | Disease prevention | Cardiovascular disease | Costs | Health care access | Preventive medicine | Health risk assessment | Klinisk medicin | Clinical Medicine
Journal Article
Thrombosis and Haemostasis, ISSN 0340-6245, 04/2009, Volume 101, Issue 4, pp. 714 - 719
Journal Article
by Anand, Sonia S and Bosch, Jackie and Eikelboom, John W and Connolly, Stuart J and Aboyans, Victor and Alings, Marco and Kakkar, Ajay K and Lewis, Basil S and Störk, Stefan and Zhu, Jun and Lopez-Jaramillo, Patricio and O'Donnell, Martin and Commerford, Patrick J and Vinereanu, Dragos and Ryden, Lars and Misselwitz, Frank and Varigos, John D and Vanassche, Thomas and Chen, Edmond and Branch, Kelley and Leong, Darryl P and Bangdiwala, Shrikant I and Hart, Robert G and Yusuf, Salim and CARTASEGNA, LUIS and VICO, MARISA and HOMINAL, MIGUEL ANGEL and HASBANI, EDUARDO and CACCAVO, ALBERTO and VOGEL, DANIEL and HRABAR, ADRIAN and CUNEO, CARLOS and MACKINNON, IGNACIO J and AHUAD GUERRERO, RODOLFO ANDRES and COSTABEL, JUAN PABLO and BARTOLACCI, INES PALMIRA and BARBIERI, MARIA and GOMEZ VILAMAJO, OSCAR and GARCIA DURAN, RUBEN OMAR and SCHIAVI, LILIA BEATRIZ and INGARAMO, ADRIAN and BORDONAVA, ANSELMO PAULINO and PELAGAGGE, MARIA JOSE and NOVARETTO, LEONARDO and ALBISU DI GENNERO, JUAN PABLO and IBANEZ SAGGIA, LUZ MARIA and ALVAREZ, MOIRA and VITA, NESTOR ALEJANDRO and MACIN, STELLA MARIS and CARDONA, MARCELO and SARJANOVICH, RODOLFO JUAN and CUADRADO, JESUS and LITVAK BRUNO, MARCOS RAUL and CHACON, CAROLINA and MAFFEI, LAURA ELENA and GRINFELD, DIEGO and VENSENTINI, NATALIA and MAJUL, CLAUDIO RODOLFO and LUCIARDI, HECTOR LUCAS and FERRE PACORA, FREDY ANTONI and VAN DEN HEUVEL, PAUL and VERHAMME, PETER and DEBONNAIRE, PHILIPPE and VAN DE BORNE, PHILIPPE and LEROY, JEAN and SCHROE, HERMAN and ELEGEERT, IVAN and HOFFER, ETIENNE and DUJARDIN, KARL and ABRANTES, JOSE ANTONIO and MANENTI, EULER and MAIA, LILIA and HERNANDES, MAURO and ROSSI DOS SANTOS, FABIO and ZIMMERMANN, SERGIO LUIZ and ABIB JR, EDUARDO and LEAES, PAULO and BOTELHO, ROBERTO and BRAILE, MARIA and IZUKAWA, NILO and TANAJURA, LUIZ FERNANDO and SERRANO JUNIOR, CARLOS VICENTE and NASI, LUIZ ANTONIO and TYTUS, RICHARD and PANDEY, SHEKHAR and LONN, EVA and CHA, JAMES and BABAPULLE, MOHAN and LAMY, ANDRE and KIAII, BOB and BHARGAVA, RAKESH and MEHTA, PRAVINSAGAR and HILL, LAURIE and FELL, DAVID and LAM, ANDY and AL-QOOFI, FAISAL and PETRELLA, ROBERT and GLANZ, ANTHONY and NOISEUX, NICOLAS and MERALI, FATIMA and ... and COMPASS Investigators and Sahlgrenska akademin and Institute of Medicine, Department of Molecular and Clinical Medicine and Institutionen för medicin, avdelningen för molekylär och klinisk medicin and Göteborgs universitet and Gothenburg University and Sahlgrenska Academy
The Lancet (British edition), ISSN 0140-6736, 2018, Volume 391, Issue 10117, pp. 219 - 229
...) inhibitors, and antiplatelet agents (aspirin or a P2Y12 inhibitor) are used to reduce vascular complications.4-6 
MORTALITY | MEDICINE, GENERAL & INTERNAL | METAANALYSIS | MANAGEMENT | THERAPY | OUTPATIENTS | CARDIOVASCULAR EVENT RATES | PREVENTION | RISK | Myocardial Infarction - epidemiology | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Carotid Artery Diseases - complications | Male | Peripheral Arterial Disease - complications | Rivaroxaban - administration & dosage | Aspirin - administration & dosage | Factor Xa Inhibitors - administration & dosage | Incidence | Dose-Response Relationship, Drug | Rivaroxaban - adverse effects | Aspirin - adverse effects | Platelet Aggregation Inhibitors - administration & dosage | Cardiovascular Diseases - mortality | Female | Stroke - epidemiology | Aspirin - therapeutic use | Lower Extremity - surgery | Drug Therapy, Combination | Platelet Aggregation Inhibitors - therapeutic use | Myocardial Infarction - etiology | Rivaroxaban - therapeutic use | Carotid Artery Diseases - drug therapy | Platelet Aggregation Inhibitors - adverse effects | Stroke - prevention & control | Double-Blind Method | Drug Administration Schedule | Peripheral Arterial Disease - drug therapy | Carotid Artery Diseases - epidemiology | Morbidity | Factor Xa Inhibitors - therapeutic use | Stroke - etiology | Peripheral Arterial Disease - epidemiology | Factor Xa Inhibitors - adverse effects | Aged | Myocardial Infarction - prevention & control | Amputation - statistics & numerical data | Hemorrhage - chemically induced | Lower Extremity - blood supply | Cardiac arrhythmia | Anticoagulants | Aspirin | Stroke | Heart attacks | Medical imaging | Mortality | Clinical trials | Cardiovascular disease | Patients | Disease control | Evidence-based medicine | Carotid arteries | Disease prevention | Coronary vessels | Blood pressure | Carotid artery | Acute coronary syndromes | Thromboembolism | Health risk assessment | Cardiovascular Diseases | Factor Xa Inhibitors | Klinisk medicin | Hemorrhage | epidemiology | Rivaroxaban | administration & dosage | Combination | Amputation | Drug | drug therapy | chemically induced | complications | prevention & control | Peripheral Arterial Disease | etiology | Clinical Medicine | Myocardial Infarction | statistics & numerical data | blood supply | Carotid Artery Diseases | Platelet Aggregation Inhibitors | adverse effects | mortality | Lower Extremity | Dose-Response Relationship | therapeutic use | surgery
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2009, Volume 374, Issue 9694, pp. 989 - 997
Summary Background Proton-pump inhibitors (PPIs) are often prescribed in combination with thienopyridines... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | THERAPY | PLATELET-AGGREGATION | OF-FUNCTION POLYMORPHISM | OMEPRAZOLE | THROMBOLYSIS | ACUTE CORONARY SYNDROMES | OUTCOMES | ANTIPLATELET ACTION | ATORVASTATIN | Multivariate Analysis | Prasugrel Hydrochloride | Thiophenes - therapeutic use | Thiophenes - adverse effects | Ticlopidine - therapeutic use | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Male | Pyridines - adverse effects | Drug Interactions | Ticlopidine - adverse effects | Cardiovascular Diseases - epidemiology | Female | Platelet Aggregation - drug effects | Drug Therapy, Combination | Platelet Aggregation Inhibitors - therapeutic use | Platelet Aggregation Inhibitors - adverse effects | Pyridines - therapeutic use | Proton Pump Inhibitors - adverse effects | Risk Factors | Kaplan-Meier Estimate | Proportional Hazards Models | Logistic Models | Treatment Outcome | Piperazines - therapeutic use | Proton Pump Inhibitors - therapeutic use | Piperazines - adverse effects | Ticlopidine - analogs & derivatives | Randomized Controlled Trials as Topic | Acute Coronary Syndrome - drug therapy | Aged | Complications and side effects | Clopidogrel | Proton pump inhibitors | Dosage and administration | Pharmacology | Research | Properties | Studies | Data collection | Data analysis | Drug therapy | Acute coronary syndromes | Clinical outcomes | Cytochrome | Myocardial infarction | Cerebral infarction | Stroke | Funding | Clinical trials | Platelet aggregation | Agglomeration | Patients | Evidence-based medicine | Randomization | Blood platelets | Infarction | Inhibition | Index Medicus | Abridged Index Medicus
Journal Article